Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

  • Antimicrob Agents Chemother. 2002 Sep;46(9):3057-60. doi: 10.1128/AAC.46.9.3057-3060.2002.
William E Delaney 4th  1 ,  Ros Edwards ,  Danni Colledge ,  Tim Shaw ,  Phil Furman ,  George Painter ,  Stephen Locarnini
Affiliations
  • 1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia.
PMID: 12183271 DOI: 10.1128/AAC.46.9.3057-3060.2002
Abstract

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 +/- 9.5 and 2.40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

Products